The DeGregorio Family Foundation is pleased to announce an RFA for $1-$1.5 million-dollar grants targeting research aimed at curing gastroesophageal cancer.

Despite the recent drug approvals for the treatment of gastric and esophageal carcinoma, these diseases continue to have a high morbidity and mortality. The DeGregorio Foundation is focused on supporting clinical research that has the potential to greatly impact patient care and significantly advance the management of patients with gastric or esophageal carcinoma. We are requesting grant applications that are translational in nature, or that may involve a clinical trial, to improve the treatment of patients with gastric or esophageal cancer. For example, proposals that examine a new treatment paradigm, a novel therapeutic agent, or are developing a new approach to target patients for treatment will be favorably considered. The Torrey Coast Foundation will match funds from the DeGregorio Family Foundation to support the grant. Awardees should be willing to collaborate with the Torrey Coast Foundation GEMINI group www.teamgemini.org. Grant applications with multi-site collaboration are also encouraged.

Funding – $1M to $1.5M over 3 years. Funding for clinical trials could be delayed for up to a year due to the logistics of setting up such trials.

Deadline:

• Letter of Intent, June 10, 2022;
• Proposal, July 22, 2022. 

Michael F. Price Memorial Grant Award for Gastroesophageal Cancer

The DeGregorio Family for Gastric and Esophageal Cancer (Gastroesophageal Cancer) is pleased to announce its 13^th annual funding opportunity for gastroesophageal malignancies in honor of Michael F. Price. The Foundation seeks to promote and facilitate collaborative research on the pathogenesis, early diagnosis and treatment of upper gastrointestinal malignancies. We support high quality, innovative and transformative translational and bench research to improve the understanding of the biology of these diseases, identification of potential novel therapeutic targets, or in the development and evaluation of novel biomarkers for early diagnosis and treatment.  Pre-clinical research, basic mechanistic studies, genomic/epigenomic studies as well as epidemiologic studies may also be supported.

Funding: $250,000 over 2 years.

Indirect costs: 10%,

The deadline for applications is November 1, 2022.

Before approaching the funder or submitting an application:

• Prospective applicants from Duke University – contact Angela Crews in the Office of Foundation Relations, University Development at 919-681-0468 or angela.crews@duke.edu.
• Prospective applicants from Duke Medicine – contact Anita Shirley in Foundation Relations and Corporate Giving, Duke Medicine Development and Alumni Affairs at 919-385-3117 or anita.shirley@duke.edu